This week, the ratings of 10 Pharmaceuticals stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Slipping from a C to a D rating, Jazz Pharmaceuticals Plc (JAZZ) takes a hit this week. Jazz Pharmaceuticals Plc is a specialty pharmaceutical company focused on developing and commercializing products to meet medical needs in neurology and psychiatry. For more information, get Portfolio Grader’s complete analysis of JAZZ stock.

Concordia International Corp. (CXRX) earns a F this week, moving down from last week’s grade of D. The company also gets F’s in operating margin growth and earnings growth. For more information, get Portfolio Grader’s complete analysis of CXRX stock.

This week, Horizon Pharma plc (HZNP) drops from a C to a D rating. Horizon Pharma plc is a biopharmaceutical company that is developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of HZNP stock.

Intersect ENT Inc (XENT) gets weaker ratings this week as last week’s D drops to a F. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of XENT stock.

Tetraphase Pharmaceuticals, Inc. (TTPH) is having a tough week. The company’s rating falls from a D to a F. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of TTPH stock.

Aralez Pharmaceuticals Inc. (ARLZ) slips from a D to a F this week. The company also gets F’s in operating margin growth, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ARLZ stock.

Lipocine, Inc. (LPCN) declines this week from a B to a D. Lipocine, Inc. is engaged in the development of pharmaceutical products in the areas of men’’s and women’’s health. The company also gets F’s in earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of LPCN stock.

This is a rough week for AcelRx Pharmaceuticals, Inc. (ACRX). The company’s rating falls to D from the previous week’s C. AcelRx Pharmaceuticals, Inc. focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ACRX stock.

This week, Marinus Pharmaceuticals Inc’s (MRNS) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of MRNS stock.

Alimera Sciences, Inc.’s (ALIM) rating weakens this week, dropping to a F versus last week’s D. Alimera Sciences, Inc. engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company also gets F’s in earnings revisions and free cash flow. For more information, get Portfolio Grader’s complete analysis of ALIM stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.